Benzinga | Dec 1, 2020 07:38AM EST

Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, will be presented at the 17th Global Cardiovascular Clinical Trialists Forum (CVCT) by John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, COSMIC-HF and GALACTIC-HF. CVCT is a global invitation-only meeting of opinion leaders across clinical research, industry and regulatory authorities.

Session Title Targeting the Vessels and the Heart: Oral Soluble Guanylate Cyclase Stimulator (Vericiguat) and Cardiac Myosin Activation (Omecamtiv Mecarbil)

Presentation Title GALACTIC-HF Main Results

Presenter John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, COSMIC-HF and GALACTIC-HF

Date Sunday, December 6, 2020

Time 3:30 PM Central European Time